OBJECTIVES: People with serious illnesses often experience spiritual and emotional pain, manifesting in conditions such as depression, anxiety, and demoralization. Emerging research in psychedelic-assisted therapy has shown efficacy in treating these conditions. Despite evidence that psychedelics frequently occasion mystical/spiritual experiences in participants, there has been little research...
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy with limited long-term success. Psilocybin-assisted psychotherapy (PAP) is an emerging approach to nicotine cessation with a growing evidence base. As PAP research expands, understanding how nicotine users' attitudes shape treatment engagement...
Background: Psychedelic-assisted psychotherapy has shown promising results for treating alcohol use disorder (AUD) and other mental health conditions. Although the precise mechanisms of psychedelic therapies remain unclear, many studies report increased feelings of connectedness following psychedelic experiences. Specifically, both nature relatedness (one’s subjective sense of being connected...
PsychoactivesDecember 24, 2025Brendan Driscoll, Shaheen E. Lakhan1 citation
Psychedelic-assisted therapy offers rapid and profound benefits for treatment-resistant psychiatric conditions but remains constrained by the need for intensive, clinic-based administration. Concurrently, advances in digital health technologies have introduced scalable tools. This systematic review evaluates the safety, efficacy, and implementation of digitally enabled psychedelic-assisted...
Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative experiences of people participating in a study of psilocybin‐assisted psychotherapy (PAT) to treat MA use disorder. Design and setting Qualitative study of participants enrolled in a single arm, open‐label pilot study of PAT for MA use disorder...
Psychedelic-assisted therapy (PAT) has emerged as a promising and innovative approach to treating a range of mental health disorders, including depression, post-traumatic stress disorder (PTSD), and substance use disorders. Once sidelined due to regulatory bans and social stigma, psychedelics such as psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and...
Background Obsessive–compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, atypical antipsychotic augmentation and cognitive–behavioural therapy. However, up to 60% of people with OCD do not respond to these treatments. Therefore, a novel intervention, psilocybin-assisted psychotherapy (PAP), is an option of interest....
This qualitative study of how successful Psychedelic Assisted Psychotherapy (PAP) transforms the way of life of terminally ill subjects provides new knowledge for researchers and clinicians contemplating its use. Using an interpretive phenomenological approach (IPA) and interviews with subjects before and after PAP from a recent randomised control trial, we find that participants with extreme...
Psychedelics, historically used for transcendent experiences, have garnered renewed interest for their potential therapeutic applications, particularly in treating mental health conditions such as depression, PTSD, and addiction. Despite initial enthusiasm in the mid-20th century, the War on Drugs led to a decades-long hiatus in research. However, recent studies have demonstrated promising...
Introduction Psychedelic Assisted Psychotherapy (PAP) has been legal in Switzerland since 2014 under supervised exceptional medical use with MDMA, LSD and Psilocybin with case by case authorisations delivered from the Federal Office of Public Health. In particular, since 2021, we have implemented a clinical activity at Geneva University Hospital (HUG) for treatment resistant patients using LSD...